title: Beneficial effects of angiotensin II type 1 receptor blocker antihypertensive treatment on inflammation indices: the effect of smoking.
abstract: The effect of long-term angiotensin II type 1 receptor blocker (ARB) therapy on inflammation indices has not been fully investigated in a hypertensive population. The authors evaluated 323 consecutive nondiabetic patients (mean age, 57 years; 176 men; 92 smokers) with high renin activity and uncomplicated essential hypertension whose blood pressure levels normalized (from 163.9/100.7 mm Hg to 131.6/82.8 mm Hg) after 4 weeks of ARB or ARB/diuretic treatment. All patients underwent full laboratory evaluation (routine examination of blood and urine, liver, kidney, thyroid function, and lipid and glucose profiles), including measurement of high-sensitivity C-reactive protein and serum amyloid A levels, at drug-free baseline, which was repeated after 6 months of ARB or ARB/diuretic treatment. A significant (P<.001) overall decrease was noted in both high-sensitivity C-reactive protein (-0.41+/-1.56 mg/dL) and serum amyloid A (-0.62+/-2.03 mg/dL), but a smaller decrease in high-sensitivity C-reactive protein and serum amyloid A change was seen in the smoker subgroup compared with nonsmokers (P<.05), indicating that the ARB or ARB/diuretic anti-inflammatory effect may be adversely affected by smoking status.
authors.affiliation: Hypertension Unit, First Cardiology Department, Athens Medical School, Hippokration Hospital, First Cardiology Department of Onassis Cardiosurgery Center, Athens, Greece. kyvelou113@yahoo.gr
authors.forename: Stella-Maria G
authors.initials: SM
authors.lastname: Kyvelou
authors.forename: Gregory P
authors.initials: GP
authors.lastname: Vyssoulis
authors.forename: Eva A
authors.initials: EA
authors.lastname: Karpanou
authors.forename: Dionysios N
authors.initials: DN
authors.lastname: Adamopoulos
authors.forename: Theodoros P
authors.initials: TP
authors.lastname: Gialernios
authors.forename: Panagiota G
authors.initials: PG
authors.lastname: Pietri
authors.forename: Dennis V
authors.initials: DV
authors.lastname: Cokkinos
authors.forename: Christodoulos I
authors.initials: CI
authors.lastname: Stefanadis
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D002097:C-Reactive Protein / Q000187:drug effects / Q000378:metabolism*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D007249:Inflammation / Q000097:blood* / Q000150:complications; D008297:Male; D008875:Middle Aged; D012307:Risk Factors; D000685:Serum Amyloid A Protein / Q000187:drug effects / Q000378:metabolism*; D012907:Smoking / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D015415:Biomarkers; D000685:Serum Amyloid A Protein; D002097:C-Reactive Protein